Background The predominant X-linked form of dyskeratosis congenita results from mutations in dyskerin, a protein required for ribosomal RNA modification that is also a component of the telomerase complex. We have previously found that expression of an internal fragment of dyskerin (GSE24.2) rescues telomerase activity in X-linked dyskeratosis congenita (X-DC) patient cells. Materials and Methods Here, we have generated F9 mouse cell lines expressing the most frequent mutation found in X-DC patients, A353V and study the effect of expressing the GSE24.2 cDNA or GSE24.2 peptide on telomerase activity by TRAP assay, and mTERT and mTR expression by Q-PCR. Point mutation in GSE24.2 residues were generated by site-directed mutagenesis. Results Expression of GSE24.2 increases mTR and to a lesser extent mTERT RNA levels, and leads to recovery of telomerase activity. Point mutations in GSE24.2 residues known to be highly conserved and crucial for the pseudouridine-synthase activity of dyskerin abolished the effect of the peptide. Recovery of telomerase activity and increase in mTERT levels were found when the GSE24.2 peptide purified from bacteria was introduced into the cells. Moreover, mTR stability was also rescued by transfection of the peptide GSE24.2. Discussion These data indicate that supplying GSE24.2, either from a cDNA vector, or as a peptide, can reduces the pathogenic effects of Dkc1 mutations and could form the basis of a novel therapeutic approach.
Introduction
Telomeres are nucleoprotein complexes located at the ends of linear chromosomes and consist of tandem repeats of R. Machado-Pinilla and J. Carrillo contributed equally to this manuscript.
simple DNA sequences (TTAGGG in humans) and proteins that interact directly or indirectly with these sequences [1] . Sequence erosion of terminal repeats takes place in each round of genome replication. The replenishment of telomeric repeats is accomplished by extension of their 3 0 ends, through a reaction mediated by the telomerase complex [2] . In humans, the active telomerase complex consists of a minimum of three essential components: hTERT, hTR and dyskerin [3] . Besides forming part of the telomerase complex, dyskerin is a pseudouridine-synthase, a component of H/ACA small nuclear RNPs [4] , complexes that mediate the conversion of specific uridines (U) to pseudouridine in newly synthesized ribosomal RNA [5] [6] [7] . Point mutations in dyskerin cause a rare X-linked recessive disease named X-dyskeratosis congenita [8] . Individuals with X-DC display features of premature ageing, as well as nail dystrophy, mucosal leukoplakia, interstitial fibrosis of the lung, bone marrow failure and increased cancer susceptibility, form head and neck and gastrointestinal tumors [9] . The tissues affected by X-DC, such as bone marrow and skin, are characterized by the high turnover of their progenitor cells.
We previously isolated a peptide GSE24.2, in a screen of cDNAs for those that confer survival ability on cells treated with cisplatin. Intriguingly GSE24.2 turned out to be a short dyskerin fragment containing 2-highly conserved motifs implicated in pseudouridine-synthase catalytic activity. GSE24.2 prevents telomerase inhibition mediated by different drugs including cisplatin and telomerase inhibitors. In X-DC and WI-38-VA13 cells, GSE24.2 induces an increase in hTERT and hTR levels and recovery of telomerase activity [10] . To obtain more information on the biological activity of this dyskerin fragment, we have generated a mouse-F9 cell line carrying the A353V mutation in the Dkc1 gene. This is the mutation most frequently found in patients with X-DC [11, 12] and is localized in the PUA RNA-binding domain, the putative site for interaction with hTR. This mutation in mouse ES cells leads to severe destabilization of mTR, a reduction in telomerase activity and a significant continuous loss of telomere length during in vitro cell culture [13] . In addition, causes a decrease in the accumulation of a subset of H/ACA small nucleolar RNAs, and a significant decrease in site-specific pseudouridylation efficiency [13] . Here, we show that expression of GSE24.2 is able to induce a recovery in telomerase activity in F9-X-DC mouse cell line model, by increasing mTR and mTERT RNA levels. Moreover, a peptide encoding GSE24.2, when introduced into mutant cells, is able to rescue telomerase activity and also destabilization of mTR induced by the Dkc1 mutation suggesting that expression of GSE24.2, could prolong the lifespan of X-DC cells and protect from associated malignancies.
Materials and methods
Constructs, generation of F9 A353V cells and cell culture GSE24.2, DKC, motif I and motif II were cloned as previously described [10] . The hTERT promoter construct was a gift from Dr. T. Kim [14] ; the hTR promoter construct was a gift from Dr. N. Keith [15] ; PGATEV protein expression plasmid [16] was obtained from Dr. G. Montoya. PGATEV-24.2 was obtained by subcloning the 24.2 fragment into the NdeI/XhoI sites of the pGATEV plasmid.
F9 cells were transfected with A353V targeting vector and selected as previously described for constructing the mouse ES cell line containing the A353V mutation [13] . F9A353V cells were cultured in Dulbecco modified Eagle medium (DMEM) 10 % fetal bovine serum, 2 mM glutamine (Gibco) and sodium bicarbonate (1.5 g/ml)
Cell transfections and analysis of gene expression F9 cells were transfected with 16 lg of DNA/10 6 cells, using lipofectamine plus (Invitrogen, Carslbad, CA, USA), according to the manufacturer's instructions. Protein extracts were prepared and luciferase activity determined using a commercial kit (Promega, Madison, WI, USA). Each assay was performed in triplicate, and repeated in three different experiments. Transfection efficiencies were corrected by co-transfection of p-CMV-Renilla. 293T cells were transfected by the calcium phosphate procedure and protein extracts were obtained 24 h later as described above. Transfection of GSE24.2 peptide was performed by using the Transport Protein Delivery Reagent (50568; Lonza) transfection kit. Routinely from 6 to 15 lg were used per 35 mm dish.
Antibodies
Anti-dyskerin and anti topoisomerase IIb (Ab7471) were from Abcam, (Cambridge, UK).
Site-directed mutagenesis
Mutation of single nucleotides of the GSE24.2 was performed using the Quickchange X-L site-directed mutagenesis kit (Stratagene, Santa Clara, CA, USA) according to the manufacturer's instructions.
Telomeric repeat amplification protocol (TRAP) assay
Telomerase activity was measured using the TRAPeze kit [17] (Intergen, Purchase, NY, USA) (Serologicals, Norcross, GA, USA) according to the manufacturer's recommendations. TRAP assay activity was normalized for total protein concentration [10] .
GSE24.2 peptide production and purification
Escherichia coli Rosetta-gami 2 competent cells were transformed with pGATEV GSE24.2 and lysates prepared as described [16] . The fusion protein was purified with glutathion-sepharose and purity analyzed by gel electrophoresis. GSE24.2 was obtained and purified as described [16] .
Western blot
Whole-cell extracts were prepared essentially as described previously [18] . Nuclear extracts were obtained as previously reported [10] . Western blotting was performed using standard methods [18] . Protein concentration was measured by using the Bio-Rad protein assay. Each cDNA sample was analyzed in triplicate using StepOne Plus Real Time PCR System (Applied Biosystems) and relative gene expression quantification was calculated according to the comparative threshold cycle method (2 ÀDDC t ), where DDC t = DC t gene expression -DC t control, using b-actin as endogenous control.
Results

Induction of the Dkc1 A353V mutation in F9 cells
We chose to create mouse F9 cells containing the recurrent Dkc1-A353V mutation in order to study the molecular consequences of this mutation and the puzzling effects of the GSE24.2 peptide on cells with Dkc1 mutations. From the targeting experiment, a single F9 cell line was isolated that was successfully targeted. This cell line was shown to contain a single Dkc1 gene, which contains the mutation causing the A353V change, by Southern blot, PCR and sequencing. Figure 1 shows that the correctly targeted cell line, cell line 40, has decreased dyskerin mRNA (Fig. 1a) and protein ( Fig. 1b) and dramatically decreased amounts of mTR (Fig. 1a) , compared with control cell lines. Cell line 40 also contains reduced telomerase activity (Fig. 1c) . We therefore used this cell line, hereafter called F9A353V, for the experiments described in this manuscript.
GSE24.2 expression in F9 and F9A353V cells results in stimulation of telomerase catalytic activity
We did not observe any obvious difference in the growth rate or any morphological changes in the F9A353V cells as compared with wild-type F9 cells (data not shown). We previously reported that expression of GSE24.2 increases telomerase activity in X-DC human-derived fibroblasts [10] . To extent this observation to A353V mutation, we transfected F9A353V and control cells with a plasmid expressing GSE24.2. Remarkably, we found that GSE24.2 expression significantly increased telomerase activity in both F9A353V and F9 cells (Fig. 2a, see asterisks) . It has been previously described that overexpression of dyskerin in cells lacking telomerase activity does not stimulate telomerase activity [10, 19] , so we were interested to see the effect of dyskerin overexpression in F9 cells. Surprisingly, expression of dyskerin in F9 cells significantly increases telomerase activity (Fig. 2a) but the increment is not observed in F9A353V (Fig. 2a) , perhaps indicating a dominant negative effect of the A353V mutation. Expression of GSE24.2 increases mTERT mRNA and mTR levels in F9A353V cells and this correlates with the increment observed in telomerase activity indicating that telomerase complexes although lacking wild type dyskerin, may be more stable. Overexpression of dyskerin induces a mild increase in mTR levels in F9 cells, which could correlate with the small increase observed in telomerase activity (Fig. 2a, b) . We next studied the activity of hTERT promoter in F9 and F9A353 V cells using a luciferase reporter construct containing the hTERT promoter. hTERT transcription is activated by GSE24.2, suggesting that the increase in mTERT levels could to be due to activation of mTERT transcription (Fig. 2c) . Over-expression of dyskerin does not have any effect on hTERT promoter activity. As the promoter of hTERT-telomerase component was constitutively activated in GSE24.2 expressing cells in a c-myc expression-dependent manner [10] , we studied the effect of GSE24.2 expression on c-Myc promoter activity in F9 and F9A353V cells. We measured the activation of this promoter using a construct containing 3.2 Kb of the c-Myc regulatory region, followed by the luciferase gene (Fig. 2d) . GSE24.2 also activates c-myc promoter in both cell lines. We also performed a luciferase assay using a construct that contained the hTR promoter followed by the luciferase gene. No activation of hTR promoter mediated by the GSE24.2 was observed in any of the cell lines, in agreement with previous results (Fig. 2e) suggesting that the increment in mTR levels should be due to stabilization of the RNA.
Recovery of telomerase activity by GSE24.2 requires a complete and intact pseudouridine synthase domain The GSE24.2 peptide corresponds to an internal fragment of dyskerin, which contains the pseudouridine-synthase domain TRUB. This comprises two highly conserved motifs; motif I is essential for the maintenance of the structural stability of the protein while motif-II contains at least one residue essential for the enzymatic activity [20] [21] [22] . We asked which of these motifs was responsible for the activation of telomerase activity in Dkc1 mutant cells, or whether both were required. We cloned sequences encoding the motifs independently and transiently transfected both F9 and F9A353V cells with the individual expression vectors (Fig. 3a) . Twenty-four hours after transfection, measurement of telomerase activity was performed using TRAP assay. We observed that neither of these motifs alone induced a recovery of telomerase (Fig. 3b) . We could not observe activation of hTERT or c-MYC transcription in contrast to our results with the whole domain (Fig. 3c) [10] .
We next asked if substitution of specific amino acid residues, affected the activity of GSE24.2 by performing site directed mutagenesis to alter TRUB domain aminoacid residues that are essential for pseudouridine-synthase activity and highly conserved through evolution. Therefore, K96 in motif-I and D125 in motif-II were substituted for valine by site-directed mutagenesis (Fig. 4a) . First of Fig. 1 Characterization of F9-derived cell lines: a northern blots of different cell lines obtained from the targeting experiment. 1.6 % agarose formaldehyde gels were run and blotted and probed for dyskerin, mTR and 5S RNA as a loading control. The cell lines were WT, the parental F9 cells; 63, a neomycin resistant cell line not targeted at the Dkc1 locus; 64, a neomycin resistant cell line lacking the A353V mutation that had contained and had lost the neomycin resistance cassette from the 3 0 UTR of Dkc1; 40, the correctly targeted A353V cell line; 42, a cell line not correctly targeted but containing multiple inserted targeting constructs. b Western blots of nuclear proteins extracted from different cell lines from the targeting experiment and probed with a mouse anti-dyskerin and a topoisomerase IIb antibody as a loading control. The cell lines were as in the legend of panel a. P indicates the passage number. c Telomerase activity was measured in cell extracts from different cell lines from the targeting experiment using the TRAPEZE protocol. The cell lines were as described in panel a. Control lanes: 1 TRS8 positive control, 2 negative control (Chaps buffer), 3 HeLa positive control, 4 inactivated HeLa extracts all, we studied the effect of these mutations on GSE24.2-mediated telomerase activation. We transiently transfected F9 and F9A353V cells with both mutant expression vectors and 24 h after transfection we performed a TRAP assay. We observed that neither of these mutants activated telomerase (Fig. 4b) suggesting that the residues mutated that are essential for dyskerin activity are also essential for GSE24.2 activity. In order to determine the effect of the mutations on the activation of hTERT and c-MYC promoters, we transiently transfected F9 and F9A353V cells with the pLNCX, GSE24.2, 
GSE24.2(K96V) or GSE24.2(D125V) together with either
hTERT or c-MYC luciferase reporter vectors (Fig. 4c) . Both mutations impaired the activation of these promoters mediated by the GSE24.2, suggesting that these residues are very important for GSE24.2 activity. In agreement with previous results, no activation of hTR promoter by the GSE24.2 or any of the mutants was observed (Fig. 4c) , but we did not detect accumulation of mTR when we used the mutated GSE24.2 expression plasmids (not shown) suggesting that stabilization of mTR may also contribute to the increased telomerase activity caused by GSE24.2.
Transfection of purified GSE24.2 peptide stimulates telomerase activity Since GSE24.2 codes for an internal dyskerin peptide, we tested if GSE24.2 peptide purified from bacteria, would have the same effect on telomerase activity as expression of the plasmid containing GSE24.2 cDNA. Initially, we used 293T cells, because of their high transfection efficiency. Cells were transfected with the construct containing the c-MYC promoter and 24 h later transfected with the GSE24.2 peptide and luciferase activity was assayed 6 h later. The results showed activation of c-MYC promoter in cells transfected with GSE24.2 peptide, indicating that the induction observed when we transfected GSE24.2 cDNA (Fig. 5a ) is indeed due to its translation into a protein.
We assayed the stability of the transfected peptide by testing its activity on the c-myc promoter, and found that the activity of the peptide lasted until 72 h after transfection (Fig. 5b ). This correlated with an increase in mTERT and c-myc transcription estimated by q-RT-PCR (Fig. 5c, d) . Then, X-DC dermal human fibroblast were transfected with GSE24.2 peptide and 4 h later assayed for telomerase activity. The peptide was efficient in activating telomerase activity in X-DC cells (Fig. 5e) as also happened when cells were transfected with GSE24.2 cDNA [10] . We then transfected F9 and F9A353V cells with GSE24.2 peptide and measured telomerase activity using the TRAP assay. We observed that there was an increment in telomerase activity after the transfection with GSE24.2 peptide in both cell lines (Fig. 5f, see asterisks) . Heat inactivated GSE24.2 peptide did not induce a recovery in telomerase activity (data not shown) indicating that GSE24.2 peptide could be used for a transient recovery of telomerase activity.
GSE24.2 peptide increases mTR stability
One of the key events affected by DKC A353V mutation was stability of mTR. However, we observed that hTR promoter activity was not changed when GSE24.2 was expressed. We wanted to investigate if this peptide was able to increase mTR stability, by assaying its effect on mTR half-life. For that purpose F9 and F9A353V cells were transfected with GSE24.2 peptide and treated with two doses of actinomycin D. Total RNA was obtained after 2 h of treatment and expression of mTR assayed by qRT-PCR. The result showed that mTR-RNA levels did not change in F9 cells after actinomycin treatment, while in F9A353V cells a decrease in mTR expression levels up to 60 % was observed, as expected (Fig. 6 ). F9A353V cells transfected with GSE24.2 peptide showed a more stable expression of mTR even after treatment with the higher dose of actinomycin D demonstrating that GSE24.2 peptide was able to increase mTR stability in the presence of a mutated Dkc1.
Discussion
The predominant X-linked form of DC results from mutations in DKC1 encoding dyskerin, a protein required for ribosomal RNA-pseudouridine modification that is also a component of the telomerase complex. Telomerase activation in X-DC cells allows telomere elongation, telomere length maintenance and allows the cells to avoid premature senescence. This activation can be mediated by the expression of both TERT and TR that forms part of the telomerase complex. Expression of wt-DKC is not able to rescue either telomerase activity or premature senescence [23] . We have previously reported that a dyskerin domain (GSE24.2) reactivates telomerase activity in cells that are deficient in this activity by increasing hTERT and hTR levels. We have also previously reported that GSE24.2 activates hTERT transcription by modulating c-MYC expression and also increases TR levels. Supporting our previous findings, we here describe that expression of this dyskerin domain is able to recover telomerase activity in a X-DC mouse cell model carrying the mutation A353V. This mutation is the most frequent in X-DC patients [24] and is located within the highly conserved archeosinetransglycosylase (PUA) RNA binding domain of the protein [25] . Here, we have found that, this mutation causes a marked decrease of mTR levels, a smaller decrease in mTERT levels and lowered telomerase activity in F9 cells. All these defects are reverted by GSE24.2 expression, as previously shown for the T66A mutation in X-DC cells [23] . The fact that GSE24.2 has the same effect on mouse and human cells [10] , and with different DKC mutations, reinforces the proposal that this highly conserved peptide is functionally active [11, 26] . Deletion and mutagenesis studies have shown that the whole structure of this domain is essential for its action on telomerase. Neither of the two motifs that form the pseudouridylation domain of dyskerin recovered telomerase activity when individually expressed. In addition, we have shown that two residues that are highly conserved among different species are essential for GSE24.2 activity. Interestingly one of these residues, D125, is essential for the pseudouridine-synthase activity of dyskerin. Therefore, an intact pseudouridine-synthase domain is required for GSE24.2 activity. The GSE24.2 peptide purified from bacteria, once transfected into cells reactivates telomerase activity through the same mechanism that we have found when we transfect the cDNA and its activity lasted at least 72 h after transfection. Interestingly, the peptide once transfected is able to increase, mTERT and c-myc levels together with increased mTR stability in F9-DKC mutant cells. These data support the idea that TR stabilization, mediated by GSE24.2 contributes efficiently to the recovery of telomerase activity in mutant cells. The fact that this peptide is able to rescue telomerase activity with the same efficiency as the cDNA does indicate that could be used to recover telomerase activity in human cells as an alternative transient, and chronic therapeutic tool to the cDNA for example for skin in X-DC patients.
Recently, it has been reported that steady state levels of TR in X-DC with different DKC mutations are lower that WT-control fibroblasts [27] . Lower levels of TR were found in these isoforms with mutations at the PUA domain such as A353V mutation and stable expression of TR transgene rescues for telomerase activity. In agreement with these findings, our observation that expression of A353V mutation in F9 cells strongly decreases mTR expression and its reversion by GSE24.2 expression as a cDNA or as a peptide, make us propose that the decrease in levels of mTR in this mouse model could be the more important cause of the defects observed in mutant cells. By reactivating telomerase activity throughout an increase of mTR stability, GSE24.2 should attenuate the impact of A353V mutation on telomere metabolism and therefore on the ability of cells to divide. Indeed, we have previously shown that expression of GSE24.2 rescues dermal X-DC cells from senescence, indicating that expression of GSE24.2 may form the basis of a useful therapeutic strategy for X-DC patients either as a permanent or as a temporary telomerase activator both for systemic and topic uses. These will also result in decreased genomic instability by preventing telomere fusions and therefore cancers associated to X-DC.
